Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, has entered into a global co-development and commercialization agreement with Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for TD-1473 and related back-up compounds for inflammatory intestinal diseases, including ulcerative colitis and Crohn’s disease. Under the terms of the agreement, Theravance Biopharma will receive an upfront payment of $100 million and will be eligible to receive...